The European Commission initiative – the EU-FASILIS Programme – has funded ImmunoSigns with a Voucher to collaborate with Modiquest in Nijmegen for an expanded pilot production of recombinant and/or native fragmented IC2 monoclonal autoantibodies.
The European Commission initiative – the EU-FASILIS Programme – has funded ImmunoSigns with a Voucher to collaborate with Modiquest in Nijmegen for an expanded pilot production of recombinant and/or native fragmented IC2 monoclonal autoantibodies.
ImmunoSigns is a Biotech company founded in 1996. We offer you help in project management and R&D activities within biotechnology and immunodetection.
The core competance of ImmunoSigns is development and production of polyclonal and monoclonal antibodies and design and production of novel immunoassays and diagnostic kits, especially within the clinical area of diabetes and obesity.